Senti Biosciences, Inc. (SNTI)

Market Cap	35.84M
Revenue (ttm)	n/a
Net Income (ttm)	-60.84M
Shares Out	26.16M
EPS (ttm)	-5.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,145
Open	1.390
Previous Close	1.390
Day's Range	1.370 - 1.420
52-Week Range	1.260 - 16.940
Beta	2.06
Analysts	Strong Buy
Price Target	8.50 (+520.44%)
Earnings Date	Nov 13, 2025

About SNTI

Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company’s product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood can...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: SNTI
• Website: https://www.sentibio.com

Analyst Summary

According to 2 analysts, the average rating for SNTI stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 520.44% from the latest price.

Price Target

$8.5

(520.44% upside)

Analyst Consensus: Strong Buy